n recent years, the incidence of acute pulmonary thromboembolism (APTE) in Japan has increased because of the westernization of diet and an increase in the older generation. 1, 2 In addition, clinician awareness of APTE and the advances in diagnostic modalities have contributed to the increased APTE morbidity. With regard to treatment of APTE, the efficacy of anticoagulation has been well-established since the classic clinical trial in 1960. 3 On the other hand, the benefit of thrombolytic therapy is unclear with regard to mortality. Many randomized controlled trials comparing thrombolysis with heparin anticoagulation in the United States and Europe have demonstrated that thrombolytic therapy is superior to heparin anticoagulation in terms of the rapid improvement of pulmonary artery obstruction and hemodynamic abnormalities in APTE patients. [4] [5] [6] [7] [8] [9] [10] [11] [12] Interestingly, some ethnic differences exist between Japanese and Western people regarding coagulability because of the lower incidence of venous thromboembolic diseases in the Japanese than in Western people. 13 Therefore, it is inappropriate to assume that the results of previous Western studies are fully applicable to the clinical situation in Japan. However, no large clinical trial for antithrombotic treatments has been performed in the Japanese population. In an attempt to resolve these issues, we retrospectively investigated the relation between antithrombotic treatments and prognosis in Japanese APTE patients.
Methods

Study Population
The subjects were patients diagnosed with APTE in the Mie University Hospital and affiliated hospitals between December 1975 and August 2000. During this period, 225 consecutive patients (84 males, 141 females) were confirmed to have APTE by the following methods: a pulmonary angiogram that disclosed a pulmonary vessel obstruction or intraluminal filling defect; by a high-probability perfusion lung scan, which was defined as 2 or more large mismatched segmental defects or the arithmetic equivalent with large or moderate defects based on the revised Prospective Investigation of Pulmonary Embolism Diagnosis criteria 14 ; by contrast computed tomography that detects intraluminal filling defects in the pulmonary artery; or by an autopsy. The average age at onset was 64.5±16.9 years (mean ± SD; range, 16-102 years). Patients who underwent pulmonary embolectomy or died of underlying diseases were not included in this analysis. In addition, we excluded patients who died within 1 h of onset because it was impossible to investigate the effect of antithrombotic treatments.
The patients were classified into 3 groups based on therapeutic strategy. The Thrombolytic Group underwent thrombolytic therapy within 24 h of APTE diagnosis. The thrombolytic agent was alteplase or urokinase. The patients receiving alteplase were given an intravenous dose of 24 million units (40 mg), of which 10% was given as a bolus and the residual 90% as an infusion for 2 h according to the 
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regimen widely used for acute myocardial infarction treatment in Japan. 15 In patients receiving urokinase, treatment with 24,000-96,000 units per day was given for 1-5 days. The Anticoagulation Group consisted of patients treated only with unfractionated heparin, which was intravenously administered for at least 5 days. The heparin infusion rate was adjusted to control the activated partial thromboplastin time to approximately 2-3-fold the upper limit of the normal range, followed by oral anticoagulation therapy (warfarin sodium). Warfarin sodium was administered to maintain an international normalized ratio of 1.5-3.0. Anticoagulation therapy and thrombolytic therapy were defined as 'antithrombotic treatment'. The remaining patients, who did not receive antithrombotic treatment at the initial APTE episode because they were not correctly diagnosed or they had contraindications for antithrombotic treatment, were included in the Non-treatment Group. Some of the contraindications included a recent puncture of a non-compressible vessel and organ biopsy, pregnancy or lactation, head trauma or cerebrovascular accident in the previous 6 months, cerebral hemorrhage history, intracranial or intraspinal surgery, bleeding disorders, uncontrolled hypertension (systolic blood pressure >200 mmHg and/or diastolic blood pressure >120 mmHg), known aneurysm, major surgery or trauma in the previous 10 days, and gastrointestinal or genitourinary bleeding during the previous 3 months. The patients were defined as having cardiogenic shock when they had hypotension (systolic blood pressure <90 mmHg or a decrease of systolic blood pressure ≥40 mmHg for <15 min), which was not caused by newly emergent arrhythmia, hypovolemia, or sepsis, accompanied by clinical signs of organ hypoperfusion and hypoxia (eg, impaired consciousness, urine output <30 ml/h, and cold and clammy extremities).
Initially, a clinical analysis was performed on the Nontreatment and Anticoagulation Groups. Because it is apparent that patient mortality with cardiogenic shock is significantly high without anticoagulation, 3 only the patients who did not have cardiogenic shock at the time of onset were included in the statistical analysis. Second, a clinical evaluation was performed on the Anticoagulation and Thrombolytic Groups, which included patients with and without cardiogenic shock.
Data Acquisition
Information about the clinical course and the diagnostic and therapeutic patient management was obtained from hospital records. Data including the clinical characteristics, treatment, rate of major bleeding, and the in-hospital mortality were collected. We could not obtain echocardiographic findings, which included right ventricular dysfunction, because all patients did not undergo this procedure. Hemorrhagic stroke and other bleeding episodes (a decrease in hemoglobin concentration ≥2 g/dl, a requirement of blood transfusion ≥2 units, retroperitoneal bleeding, a requirement of surgical intervention, and the discontinuation of antithrombotic treatment) were regarded as 'major bleeding'. Therapeutic approaches, such as the use of thrombolytic agents, dosage, and duration of the administration of antithrombotic agents, were decided by the attending physicians.
Statistical Analysis
All continuous variables were expressed as mean ± 1 standard deviation. Comparisons of proportion were performed using Fisher's exact test. Multiple logistic regression analysis was performed to investigate the independent effect of clinical characteristics and thrombolytic therapy on in-hospital mortality. The results obtained using the logistic regression models were presented as estimated odds ratios (OR) with the corresponding 95% confidence intervals (CI). P values of less than 0.05 were considered statistically significant.
Results
Comparison of Mortality Patients Without Cardiogenic Shock at the Time of Onset in the Non-Treatment and Anticoagulation Groups
Twenty-one patients in the Non-treatment Group and 24 patients in the Anticoagulation Group did not have cardiogenic shock at onset. No patients in the Non-treatment Group were correctly diagnosed at the time of the initial APTE episode. The clinical characteristics of the Nontreatment and Antithrombotic Groups are shown in Table 1 . The mean age of patients was 52.1±16.7 years in the Nontreatment Group and 66.3±13.5 years in the Anticoagulation Group (p=0.0031). There was not a significant difference in the clinical characteristics between these 2 groups, except for mean age and the ratio of patients with onset outside of the hospital. As shown in Table 2 , mortality was significantly lower in the Anticoagulation Group than in the Non-treatment Group (0% vs 33%, p=0.0026). All patients who died in the Non-treatment Group were confirmed to have APTE at the time of recurrence: by autopsy in 5 patients, pulmonary angiography in 1 and by contrast computed tomography in 1. The diagnosis of recurrent APTE in patients who were incorrectly diagnosed at the time of the initial APTE episode was based on their clinical course that showed they had another sign such as dyspnea and hypoxia, suggesting development of the initial APTE before the confirmed diagnosis of recurrent APTE was made. No patients in the Anticoagulation Group had major bleeding complications. Table 3 shows the clinical characteristics of both treatment groups. There were 144 patients, comprising 40 patients (28%) in the Anticoagulation Group and 104 (72%) in the Thrombolytic Group. The mean age of the patients was 65.3±14.0 years in the Anticoagulation Group and 57.6±15.8 years in the Thrombolytic Group (p=0.0076). There was no significant difference in demographic or clinical characteristics between these 2 groups, except for the mean age. Table 4 shows the comparison of the clinical events between these groups. Eight patients (8%) died in the Thrombolytic Group, whereas only 1 (3%) died in the Anticoagulation Group; thus, there was no statistically significant difference between the groups (p=0.44). The cause of death in 5 of 9 patients was APTE recurrence. Multiple logistic regression analysis also demonstrated that thrombolysis did not improve in-hospital outcomes. The in-hospital mortality was independently associated with the following clinical characteristics: cardiogenic shock at the time of onset (OR, 2.36; 95% CI, 1.07-5.21; p=0.0034) and old age of not less than 65 years (OR, 10.91; 95% CI, 1.34-88.76; p=0.026) ( Table 5 ). There was no significant difference in the rate of major bleeding episodes between the Anticoagulation and Thrombolytic Groups (3% vs 8%, respectively).
Anticoagulation and Thrombolytic Groups
Discussion
This was the first large retrospective clinical study concerning APTE management in Japan, including a comparison of mortality between patients receiving thrombolytic therapy and those receiving conventional heparin anticoagulation. According to the Japanese Society of Pulmonary Embolism Research, 1,2 50% of APTE patients diagnosed without autopsy undergo thrombolytic therapy and thrombolytic therapy is performed more frequently in APTE patients with cardiogenic shock in Japan. Correspondingly, 72% of the patients in this study underwent thrombolytic therapy. Although thrombolytic agents for APTE, which are not covered by public insurance in Japan, were widely used, the efficacy and safety of thrombolysis as well as anticoagulation have not been sufficiently investigated in Japan.
Of the patients who were not suffering cardiogenic shock, mortality was significantly lower in the Anticoagulation Group than in the Non-treatment Group. One-third of the Non-treatment Group patients died from APTE recurrence. Our results suggested that anticoagulation therapy could prevent APTE recurrence, which was the most important factor in improving clinical outcomes in hemodynamically stable patients. In 1960, Barritt et al reported that heparin anticoagulation significantly reduced mortality of APTE patients. 3 Subsequent studies have attested to the reduced mortality rate when heparin anticoagulation was used to treat venous thromboembolic disease 16, 17 and to the high mortality when APTE patients did not receive anticoagulant therapy. 18 Our results were consistent with those reports.
There was no significant difference in mortality between the Anticoagulation and the Thrombolytic Groups. Although a number of randomized trials have demonstrated that hemodynamic improvement occurs more rapidly in patients receiving thrombolytic therapy, there is no significant difference in the in-hospital mortality between patients receiving thrombolytic therapy and those receiving anticoagulation therapy in Western studies. [4] [5] [6] [7] [8] [9] [10] [11] [12] Our results were in agreement with those in previous reports. Although right ventricular dysfunction has recently drawn attention as a prognostic factor of APTE, [19] [20] [21] [22] [23] the relationship between thrombolysis and outcome in patients with right ventricular dysfunction was not evaluated in the present study because not all of the study subjects underwent echocardiography.
Sufficient information on APTE patients with prolonged cardiogenic shock for estimating the efficacy of thrombolytic treatment is lacking. Only one small randomized trial shows that the mortality of APTE patients with prolonged cardiogenic shock treated with streptokinase is significantly reduced compared with that of APTE patients treated with heparin. 24 Although performing a large-scale, prospective randomized trial is necessary to demonstrate the effectiveness of thrombolysis, it is ethically difficult to treat life-threatening patients with only random therapy, which potentially includes an insufficient treatment regimen. Therefore, we might have no choice but to employ thrombolytic treatments in APTE patients with prolonged cardiogenic shock.
On the other hand, we have demonstrated that cardiogenic shock at the time of onset was a predictor of in-hospital mortality rather than prolonged cardiogenic shock observed until treatment initiation. Therefore, our results indicate that the management strategy could be based on the hemodynamic state at the time of onset. A more aggressive treatment is recommended when cardiogenic shock is observed at the time of onset with or without cardiogenic shock at treatment initiation.
The most critical complication of antithrombotic treatments is hemorrhage. One meta-analysis of APTE treatment indicates that 12.9% of patients undergoing thrombolysis had a major bleeding episode compared with 8.6% of patients treated with heparin anticoagulation. 25 In the present patients, the incidence of major bleeding in patients receiving antithrombotic treatments was lower than that described in previous reports. The most important difference between our study and others was the antithrombotic agent dosage. In the US, doses of antithrombotic agents are higher than those used in Japan; for example, 100 mg of alteplase is generally used for APTE patients in the US, whereas only 40 mg is used in Japan. Consequently, the lower frequency of bleeding complications in Japan might enable the use of required thrombolytic therapy in severe APTE patients.
Study Limitations
This was a retrospective and non-randomized study, and the treatment choice was left to the discretion of the attending physicians. With such a study design, treatment selection was likely to be biased: thrombolysis was frequently used in serious cases. The mortality of the Thrombolytic Group could be reduced if there was not such a selection bias. Furthermore, we did not investigate the association between right ventricular function and the clinical outcomes, which was done in previous reports. [19] [20] [21] [22] [23] Finally, this study included patients for 25 consecutive years. During this period there have been significant developments in APTE management: more effective tools such as inferior vena cava filters 26, 27 and venous ultrasounds 28, 29 have recently become available.
Conclusions
Anticoagulation therapy was shown to improve the prognosis in APTE patients. In addition, our results indicate that cardiogenic shock at the time of onset is a predictor of inhospital mortality. However, we could not demonstrate that thrombolytic therapy had a more favorable effect on the outcome than anticoagulation therapy. A prospective trial is necessary to investigate the efficacy of thrombolytic therapy in Japan, especially in patients with right ventricular dysfunction.
